Skip to main content
AAN.com

Abstract

Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in cells in the central, peripheral, and autonomic nervous system and visceral organs. Although clinical diagnosis was difficult until recently, an increasing number of adult cases of leukoencephalopathy have been diagnosed antemortem with NIID based on the characteristic hyperintensity in the corticomedullary junction on diffusion-weighted imaging (DWI) and confirmatory skin biopsy.1 While adult-onset NIID is characterized by slowly progressive dementia, it may also present with acute symptoms including stroke-like episodes and epileptic seizures.1,2 However, pathophysiology of acute episodes remains largely unclear. Here we report a case of NIID with distinct neurologic deficits. Whereas chronic hypoperfusion on SPECT was reported in NIID,1 we observed unexpected perfusion abnormalities using arterial spin labeling (ASL), which is a noninvasive, repeatable perfusion MRI method using magnetically labeled arterial blood water protons as endogenous tracer particles.3

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Sone J, Mori K, Inagaki T, et al. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain 2016;139:3170–3186.
2.
Toyota T, Huang Z, Nohara S, et al. Neuronal intranuclear inclusion disease manifesting with new-onset epilepsy in the elderly. Neurol Clin Neurosci 2015;3:238–240.
3.
Tada Y, Satomi J, Abe T, et al. Intra-arterial signal on arterial spin labeling perfusion MRI to identify the presence of acute middle cerebral artery occlusion. Cerebrovasc Dis 2014;38:191–196.
4.
Van Paesschen W. Ictal SPECT. Epilepsia 2004;45(suppl 4):35–40.
5.
Sanchez del Rio M, Bakker D, Wu O, et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999;19:701–707.
6.
Pollock JM, Deibler AR, Burdette JH, et al. Migraine associated cerebral hyperperfusion with arterial spin-labeled MR imaging. Am J Neuroradiol 2008;29:1494–1497.
7.
Iizuka T, Tominaga N, Kaneko J, et al. Biphasic neurovascular changes in prolonged migraine aura in familial hemiplegic migraine type 2. J Neurol Neurosurg Psychiatry 2015;86:344–353.

Information & Authors

Information

Published In

Neurology® Clinical Practice
Volume 7Number 6December 2017
Pages: e39-e42
PubMed: 29431160

Publication History

Received: February 10, 2017
Accepted: June 26, 2017
Published online: August 23, 2017
Published in print: December 2017

Permissions

Request permissions for this article.

Disclosures

K. Fujita, Y. Osaki, R. Miyamoto, Y. Shimatani, T. Abe, and H. Sumikura report no disclosures. S. Murayama serves on the editorial board of Neuropathology and receives research support from the Japanese Governmental Bureau of Health, Labor and Welfare, National Center for Geriatrics and Gerontology, National Center of Neurology and Psychiatry, and the Japanese Governmental Bureau of Education, Technology and Sports. Y. Izumi reports no disclosures. R. Kaji serves as Section Editor for Frontiers in Neurology and Associate Editor for Neurology and Clinical Neuroscience; is author on a patent re: New Generation Botulinum Toxin Preparation (A2NTX); serves on the speakers' bureau for GlaxoSmithKline, Japan, Co. Ltd.; and receives research support from the Japanese Ministry of Health, Welfare, and Labor and the Japanese Ministry of Education, Culture and Science. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Koji Fujita, MD*
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yusuke Osaki, MD*
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ryosuke Miyamoto, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yoshimitsu Shimatani, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Takashi Abe, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hiroyuki Sumikura, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Shigeo Murayama, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neuropathology, editorial board, since 2004
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The Japanese Governmental Beurearu of Helath, Labor and Welfare, Grants in aid for intractable neurological disorders,2017- 2018, coPI, structured 002, general 0-15, 058, 002, 0-15 & for mental disorders, general 004; Grants in aid provided by National Center for Geriatrics and Gerontology, 2017- 2020, PI 23-42, Co- PI 23-37; Grants in Aid provided by National Center of Neurology and Psychiatry, 2017-2018, Co PI 25-7 The Japanese Governmental Bureau of Education, Technology and Sports, New Aera, Co PI 221S003.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yuishin Izumi, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ryuji Kaji, MD
Institute of Biomedical Sciences (KF, YO, RM, YS, TA, YI, RK), Tokushima University Graduate School, Tokushima; and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (HS, SM), Tokyo, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Frontiers in Neurology, Section Editor Neurology and Clinical Neuroscience, Associate Editor
Patents:
1.
WO2008050866A1 (1) New Generation Botulinum Toxin Preparation (A2NTX)
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
(1) Glaxo-Smith Kline, Japan, Co Ltd, commercial
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Japanese Ministry of Health, Welafare, and Labor (No. 26310301) Japanese Ministry of Education, Culture and Science (No. 24390223)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to: [email protected]
*
These authors contributed equally to this work.
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Author Contributions

K. Fujita: design and conceptualization of the study, analysis and interpretation of the data, drafting and revising the manuscript. Y. Osaki: design and conceptualization of the study, analysis and interpretation of the data, drafting and revising the manuscript. R. Miyamoto: analysis and interpretation of the data, revising the manuscript. Y. Shimatani: analysis and interpretation of the data, revising the manuscript. T. Abe: analysis and interpretation of the data, revising the manuscript. H. Sumikura: analysis and interpretation of the data, revising the manuscript. S. Murayama: analysis and interpretation of the data, revising the manuscript. Y. Izumi: analysis and interpretation of the data, revising the manuscript. R. Kaji: analysis and interpretation of the data, revising the manuscript.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Clinical features of neuronal intranuclear inclusion disease with seizures: a systematic literature review, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1387399
    Crossref
  2. Diffusion and functional MRI reveal microstructural and network connectivity impairment in adult-onset neuronal intranuclear inclusion disease, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1478065
    Crossref
  3. Recovery after Prolonged Disturbance of Consciousness and Repeated Cerebral Perfusion Changes in Neuronal Intranuclear Inclusion Disease, Internal Medicine, 63, 2, (333-336), (2024).https://doi.org/10.2169/internalmedicine.1015-22
    Crossref
  4. Review of Phenotypic Heterogeneity of Neuronal Intranuclear Inclusion Disease and NOTCH2NLC-Related GGC Repeat Expansion Disorders, Neurology Genetics, 10, 2, (2024)./doi/10.1212/NXG.0000000000200132
    Abstract
  5. Reversible encephalitis-like episodes in fragile X-associated tremor/ataxia syndrome: a case report, BMC Neurology, 24, 1, (2024).https://doi.org/10.1186/s12883-024-03641-z
    Crossref
  6. The predominance of “astrocytic” intranuclear inclusions in neuronal intranuclear inclusion disease manifesting encephalopathy‐like symptoms: A case series with brain biopsy, Neuropathology, 44, 5, (351-365), (2024).https://doi.org/10.1111/neup.12971
    Crossref
  7. Encephalitis-like episodes with cortical edema and enhancement in patients with neuronal intranuclear inclusion disease, Neurological Sciences, 45, 9, (4501-4511), (2024).https://doi.org/10.1007/s10072-024-07492-x
    Crossref
  8. Case report: Neuronal intranuclear inclusion disease presenting with acute encephalopathy, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1184612
    Crossref
  9. Longitudinal course of hyperintensity on diffusion weighted imaging in adult-onset neuronal intranuclear inclusion disease patients, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1178307
    Crossref
  10. A case report of neuronal intranuclear inclusion disease with paroxysmal peripheral neuropathy-like onset lacking typical signs on diffusion-weighted imaging, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1117243
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share